ReviewPigment cell & melanoma research2025
The Roles of PTEN in Melanoma Suppression.
Review in Pigment cell & melanoma research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Therapeutic Resistance in Melanoma: Molecular Mechanisms and Emerging Pharmaceutical Strategies.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Genetic Medicine Approaches for Tumor Suppressor Loss: Therapeutic Replacement with Self-Amplifying RNA.Pharmaceutical research · 2026Review
- Promoter Methylation and Somatic Mutations in Cancer-Related Genes Are Associated with Hyperprogressive Disease in Patients with Malignant Melanoma and Renal Cell Carcinoma Receiving Anti-PD-1/PD-L1 Immunotherapy.Journal of clinical medicine · 2026Article
- The Roles of PTEN in Melanoma Suppression.Pigment cell & melanoma research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Since its discovery more than a quarter century ago, PTEN has emerged as one of the most potent tumor suppressors and its loss of function is common to numerous cancer types including glioblastoma, prostate cancer, small cell lung cancer, and melanoma. PTEN is a lipid and protein phosphatase that contributes to various cellular processes, primarily by regulating key signaling pathways. Extensive research over the past two decades has uncovered many aspects of PTEN regulation and function and highlighted the role of PTEN in tumor suppression. PTEN loss-of-function is associated with the progression of a substantial portion of melanoma cases, and while its role in melanoma suppression is often ascribed to its inhibition of the PI3K/AKT signaling pathway, recent studies may hint at a more complex role for PTEN in melanoma. In this review, we provide an overview of how PTEN suppresses melanomagenesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.